Loading company…
Olatec Therapeutics develops dapansutrile and other treatments for inflammatory diseases.
Olatec Therapeutics develops dapansutrile, an oral NLRP3 antagonist being studied for acute and chronic inflammatory diseases. Its potential treatment areas include arthritis, heart failure, asthma, Alzheimer’s disease, and multiple sclerosis. The company is based in New York, US, and was founded in 2003 by Damaris B. Skouras. In February 2023, it raised USD 40 million in Series A funding led by Sanders Morris Harris LLC, with participation from Advection Growth Capital; its lead product was in Phase 2 trials in the US and Europe as of March 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in